Amgen Bests Regeneron in Patent Fight Over Cholesterol Drugs

Updated on

Amgen Inc. won a legal victory over Regeneron Pharmaceuticals Inc. in an intellectual property battle over their cholesterol-reducing drugs. Regeneron said it would appeal the decision.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.